Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.45 |
| ▸ | FAAH | O00519 | 7/20 | 0.45 |
| ▸ | AADAC | P22760 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL3634494 | 0.97 | HRH1 (0.56) | HRH1EPHX1EPHX2FAAHAADAC | |
| SCHEMBL13703554 | 0.95 | HRH1 (0.54) | HRH1EPHX1EPHX2FAAHAADAC | |
| SCHEMBL23410168 | 0.94 | HRH1 (0.53) | HRH1EPHX1EPHX2FAAHAADAC | |
| Hydrochloric Acid SCHEMBL4324971 | 0.94 | HRH1 (0.53) | HRH1EPHX1EPHX2FAAHAADAC | |
| SCHEMBL29995753 | 0.94 | HRH1 (0.53) | HRH1EPHX1EPHX2FAAHAADAC | |
| SCHEMBL2300079 | 0.90 | CHRNB2 (0.49) | HRH1EPHX1HTR2C | |
| SCHEMBL7657873 | 0.87 | EPHX2 (0.54) | EPHX2FAAHAADACFPR2PROKR1 | |
| SCHEMBL76222 | 0.85 | HRH1 (0.54) | HRH1EPHX1EPHX2FAAHAADAC | |
| Hydrochloric Acid SCHEMBL75898 | 0.85 | HRH1 (0.54) | HRH1EPHX1IKBKBHTR2CPIM1 | |
| SCHEMBL941224 | 0.83 | HRH1 (0.57) | HRH1EPHX2IKBKBPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118688342-A | Detection method of related substances of delamani starting material | 沈阳双鼎制药有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-107406386-B | Process for producing 1- (4-hydroxyphenyl) -4- (4-trifluoromethoxyphenoxy) piperidine or salt thereof | 大塚制药株式会社 | 2021-06-01 | — | — | CN | claimed |
| EP-3275862-B1 | METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF | OTSUKA PHARMA CO LTD (JP) | 2020-08-12 | — | — | EP | claimed |
| US-10252995-B2 | Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-09 | — | — | US | claimed |
| US-20180065931-A1 | METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-03-08 | — | — | US | claimed |
| EP-3275862-A1 | METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-01-31 | — | — | EP | claimed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | claimed |
| EP-3221307-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2017-09-27 | — | — | EP | claimed |
| WO-2016079760-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-26 | — | — | WO | claimed |
| US-8592595-B2 | Preparation of (N-heterocyclyl) aryl ethers | SALTIGO GMBH (DE) | 2013-11-26 | — | — | US | claimed |
| US-20100152454-A1 | PREPARATION OF (N-HETEROCYCLYL) ARYL ETHERS | SALTIGO GMBH (DE) | 2010-06-17 | — | — | US | claimed |
| EP-2179988-A1 | Producing (N-heterocyclic) aryl ethers | Saltigo GmbH (DE) | 2010-04-28 | — | — | EP | claimed |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INST NAT SANTE RECH MED (FR) | 2025-11-20 | — | — | US | disclosed |
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-114901660-B | Substituted bicyclic compounds useful as T cell activators | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118688342-A | Detection method of related substances of delamani starting material | 沈阳双鼎制药有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-6492367-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | G. D. SEARLE & COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065931-A1 | METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF | DHPS, PAH, HPD | HRH1 227/4885EPHX1 399/4885EPHX2 1064/4885 |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | PIK3CA, PIK3R5, PIK3CD | HRH1 3298/4885EPHX1 2882/4885EPHX2 2837/4885 |
| US-10252995-B2 | Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof | DHPS, PAH, HPD | HRH1 227/4885EPHX1 399/4885EPHX2 1064/4885 |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | TALDO1, TBCA, TBCD | HRH1 4725/4885EPHX1 4012/4885EPHX2 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.